
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.






